Genitourinary (Kidney & Bladder)
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Study Protocol of a Randomized Phase III Trial of Comparing Preoperative
Liu et al. BMC Cancer (2019) 19:606 https://doi.org/10.1186/s12885-019-5728-8 STUDY PROTOCOL Open Access Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT Xiaowen Liu1,2, Jiejie Jin1,2, Hong Cai1,2, Hua Huang1,2, Guangfa Zhao1,2, Ye Zhou1,2, Jianghong Wu1,2, Chunyan Du1,2, Ziwen Long1,2, Yantian Fang1,2, Mingze Ma1,2, Guichao Li2,3, Menglong Zhou2,3, Jiliang Yin2,4, Xiaodong Zhu2,4, Ji zhu2,3, Weiqi Sheng2,5, Dan Huang2,5, Hui Zhu2,6, Zhaozhen Zhang2,7,QiLu2,8, Li Xie9, Zhen Zhang2,3* and Yanong Wang1,2* Abstract Background: The prognosis of patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma is still dismal. There are no standard treatment strategies for these patients. Multidisciplinary team (MDT) approach is a good choice for making a high-quality decision. Generally, MDT will recommend these patients to receive preoperative chemotherapy or preoperative chemoradiation based on all kinds of treatment guidelines. However, the preferred preoperative treatment is still not established. In order to solve this problem, we carry out this randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma. Methods: Eligible patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma are randomized to receive preoperative chemoradiation or preoperative chemotherapy, followed by surgery and postoperative chemotherapy. In the preoperative chemoradiation arm (Pre-CRT), patients receive two cycles of S-1 and oxaliplatin (SOX), chemoradiation, then followed by surgery and three more cycles of SOX chemotherapy. -
Honor Rolls of Best Hospitals in China Released
News Page 1 of 23 Honor rolls of best hospitals in China released Luna Young, Molly J. Wang Editorial Office,Journal of Hospital Management and Health Policy, Nanjing 210000, China Correspondence to: Molly J. Wang, Senior Editor. Editorial Office, Journal of Hospital Management and Health Policy, Nanjing 210000, China. Email: [email protected]. Received: 24 November 2017; Accepted: 03 December 2017; Published: 08 December 2017. doi: 10.21037/jhmhp.2017.12.01 View this article at: http://dx.doi.org/10.21037/jhmhp.2017.12.01 On November 11, 2017, the Honor Roll of the Best Best Comprehensive Hospitals in 2016. Comprehensive Hospitals in 2016 has been released by the In the meantime, the Honor Roll of Best Hospitals of Hospital Management Institute, Fudan University, China. Specialties in 2016 has been unveiled as well. Notably, The Honor Roll recognizes 100 hospitals for their altogether top 10 hospitals are selected in each of these exceptional comprehensive abilities where reputation of 37 specialties. The specialties range from Pathology, specialties and scientific research ability are among the Radiology, Pulmonology, Stomatology, Urology and factors predominantly weighed. Psychiatry and others with a rather comprehensive As usual, Peking Union Medical College Hospital, coverage on our daily needs. With no doubt, Peking Union West China Hospital of Sichuan University and General Medical College Hospital, West China Hospital of Sichuan Hospital of the People’s Liberation Army easily made University and General Hospital of the People’s Liberation the list, respectively ranking the top 3. Moreover, there Army, the top 3 comprehensive hospitals, are leading the are several hospitals rising greatly in the list, such as most entries of the specialties among the list. -
NCI Designated Cancer Centers International Activities
International Activities of NCI-Designated Cancer Centers Summary Report March 2014 This report is not a comprehensive summary of the international efforts of NCI-Designated Cancer Centers and not all of the efforts outlined in this report are NCI or NIH-funded. Rather, this report summarizes information that was provided by Cancer Centers who responded to requests from the NCI Center for Global Health for information on international activities. This is an ongoing data- collection effort, the data collection status for individual cancer centers can be found in Appendix A. Any additions or corrections are welcome. Please contact Rebecca Minneman ([email protected]). Table of Contents Abramson Cancer Center - University of Pennsylvania ....................................................................................4 Albert Einstein Cancer Center - Yeshiva University ..........................................................................................4 Alvin J. Siteman Cancer Center - Washington University ..................................................................................5 The Barbara Ann Karmanos Cancer Institute – Wayne State University ............................................................6 The Cancer Therapy & Research Center (CTRC) at the University of Texas Health Science Center at San Antonio (UTHSCSA) ................................................................................................................................................... 10 Case Comprehensive Cancer Center - Case Western -
The Research Relevant to Biobank GWAS in China
China Biobanking Strategy for Integrated Translational Research Rongxing Gan, Professor, MD, Director Shanghai Clinical Research Center ISBER 2014; May 21, 2014 31 Outline of Biobank Development in China 32 The strategy for China Biobanking 3 Translational Researches based on Biobank Initiatives Background Vast resources: clinical specimen on a large scale with clinical information One of the basic platforms for Translational Medical Research & New Drug Development Promote the investigation in disease mechanisms & biomarker identification Bench Bedside 2010 Clinical Specimen Repository was initiated in the 1994 The Chinese Academy of context of Significant New Drugs Development with the Medical Sciences started to work on support of the MoH and MoST establishing a bank of immortalized cell lines of Chinese ethnic groups. 2009 Beijing Municipal Science and Technology Commission launched the 1998 The Ministry of Science and construction of Beijing clinical data and Technology of China (MoST) and the sample repository of major diseases. Ministry of Health of China (MoH) drafted Human Genetic Resources 2007.9 NICGR was published online. Managements for Trial Implementation 2012 Human Genetic Resources 1998 The Office of Chinese Human 2006 MoST initiated Standardized Management Regulations (draft) was Genetic Resources Management was set organization, integration and shared formulated by the Office of Chinese under the Ministry of Science and pilot of genetic resources for Human Genetic Resources Technology of China. Significant diseases (2005-2007). Management. 1990-1995 1996-2000 2001-2005 2006-2010 2011-2015 2003 The National Infrastructure of 2008, Shanghai Municipal Science and Technology Commission Chinese Genetic Resources(NICGR) was 2012 Shanghai Biobank initiated as an important part of the launched the project of Shanghai Clinical Biobank Research Center Engineering Research Center has National Science and Technology officially granted as Shanghai Infrastructure Program by the Ministry Municipal Biobank Center by of Science and Technology of China. -
BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
BMJ Open: first published as 10.1136/bmjopen-2017-020785 on 21 October 2018. Downloaded from BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] http://bmjopen.bmj.com/ on September 26, 2021 by guest. Protected copyright. BMJ Open BMJ Open: first published as 10.1136/bmjopen-2017-020785 on 21 October 2018. Downloaded from Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced esophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2) For peer review only Journal: BMJ Open Manuscript -
The American Society for Radiation Oncology (ASTRO) Is an Accreditation Council for Continuing Medical Education (ACCME) Accred
Annual Meeting Committee Disclosure of Relationships The American Society for Radiation Oncology (ASTRO) is an Accreditation Council for Continuing Medical Education (ACCME) accredited CME provider and complies with the ACCME Standards for Commercial Support. In accordance with these Standards, the ASTRO Conflict of Interest Policy and the Council for Medical Specialty Societies’ Code for Interactions with Companies, ASTRO is disclosing here the relationships between members of the Committees charged with planning the Annual Meeting and other entities related to oncology or radiation therapy. Explanatory notes: • ASTRO uses the information disclosed to identify and manage any potential conflicts of interest that may arise in carrying out the responsibilities of the Committees. • Committee members disclose their own relationships and those of their immediate family members. • There is no “minimum value” threshold for disclosure. • Disclosure time period covers relationships held or payments received during the year leading up to the disclosure. • The disclosure information at this link is relevant only to the planning of the 2020 Annual Meeting and should be considered out- of-date after this time. • Information at this link may be different from disclosure information provided in other contexts by the Committee members because of variation in the disclosure requests for these other purposes. Employment/Leadership Positions = positions held at the time of disclosure. These include both full- and part-time relationships, whether compensated or uncompensated. Compensation/Remuneration/Funding = includes consultant/advisory roles, honoraria, research funding, travel expenses, in-kind donation, etc. If a Committee member receives an honorarium and donates it to charity, the honorarium is disclosed. If a Committee member declines an honorarium and it is paid directly to charity, the honorarium is not included. -
Long-Course Neoadjuvant Chemoradiotherapy with Versus
Wang et al. Radiation Oncology (2019) 14:215 https://doi.org/10.1186/s13014-019-1420-z RESEARCH Open Access Long-course neoadjuvant chemoradiotherapy with versus without a concomitant boost in locally advanced rectal cancer: a randomized, multicenter, phase II trial (FDRT-002) Jingwen Wang1,2†, Yun Guan3,4†, Weilie Gu1,5, Senxiang Yan6, Juying Zhou7, Dan Huang1,8, Tong Tong1,9, Chao Li10,11, Sanjun Cai1,5, Zhen Zhang1,2* and Ji Zhu1,2* Abstract Background: This study was designed to explore whether an intensified chemoradiotherapy (CRT) led to a better clinical outcome in locally advanced rectal cancer. Methods: Patients with stage II/III rectal cancer were randomly allocated to receive either pelvic intensity- modulated radiation therapy (IMRT) of 50 Gy/25Fx concurrently with capecitabine and oxaliplatin (Arm A), or pelvic radiation of 50 Gy/25Fx with a concomitant boost of 5 Gy to the primary lesion, followed by a cycle of XELOX 2 weeks after the end of CRT (Arm B). All patients were planned to receive a definitive operation 8 weeks after the completion of CRT and a total of six perioperative chemotherapy cycles of capecitabine and oxaliplatin regardless of pathological result. Pathological complete response (ypCR) was the primary endpoint. Results: From February 2010 to December 2011, 120 patients from three centers were enrolled in this study. Ninety- five percent patients completed a full-dose chemoradiotherapy as planning. Then 53 and 57 patients received a radical surgery, and 8 and 14 cases were confirmed as ypCR in two groups (P = 0.157). The other 10 patients failed to receive a definitive resection because of unresectable disease.